News

Company News

Fast Track

Qilu Pharma launched PEG-rhG-CSF

ABOUT US

Company News

Fast Track

Qilu Pharma launched PEG-rhG-CSF

Release time：

2015-09-14

Qilu Pharma has launched PEG Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rh-G-CSF) Injection, which was approved by CFDA on August 26, 2015.

Qilu Pharma passed EDQM inspection successfully

The entrepreneurs of foreign companies in Jinan visited Qilu Antibiotics Pharmaceutical Ltd.

Related News

Qilu’s Ifosfamide for Injection Joins U.S. Shortage Drug Supply, Marking the 44th FDF Export to America

2026-08-28

Qilu First Prefilled Ranibizumab Biosimilar Coming to Canada

2026-08-26

Qilu Makes NDA Breakthrough in the U.S. Market

2026-06-30

Expanded Access Policy for QLS4131 for Injection

2025-10-13

Expanded Access Policy for QLS5133 for Injection

2025-07-21

Qilu Pharma ranks No. 3 in the main business income of Chinese pharmaceutical indus

2025-07-09

Expanded Access Policy for QLS5132 for Injection

2025-06-13

Expanded Access Policy for QLS1304 Tablets

2025-05-20

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Tel: +86-531-83127705, 83127704, 83127706, 83127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

E mail：export@qilu-pharma.com, FDF@qilu-pharma.com